Web developed by Josh Bolinger website design

The Global Leader in Preclinical Ophthalmic Research


The Microemulsion Drug Ocular Penetration System (MiDROPS™) is a transformative technology for the development of eyedrop formulations.  This patented platform allows for the preparation and delivery of lipophilic agents to tissues in both the front and back of the eye.  MiDROPS™ are prepared using materials already approved by the US Food and Drug Administration for use in ophthalmic products, and by nature are intrinsically thermo-stable.



EyeCRO provides numerous in-vivo research models to enable directed and meaningful preclinical drug discovery and development programs. EyeCRO also has extensive experience in various routes of administration and can customize studies depending on your needs. One of the main advantages in working with EyeCRO is our ability to be flexible.

Research points towards new blindness prevention methods in diabetic eye disease

By combining data on optometry patient's eyes with advanced computational methods, Indiana … Read More

Detecting diabetic eye disease with machine learning

Diabetic retinopathy — an eye condition that affects people with diabetes — is the fastest growing … Read More

Cause of inflammation in diabetes identified

Inflammation is one of the main reasons why people with diabetes experience heart attacks, strokes, … Read More

More News

Wednesday, February 22nd, 2017 at 7:03am
Northwestern Medicine scientists discover retinal cell that may cause myopia https://t.co/2Ex1X3HwPp
Tuesday, February 21st, 2017 at 2:31pm
Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product $EYEG $VRX https://t.co/IWBTVG1CO2
Tuesday, February 21st, 2017 at 11:30am
The #MiDROPS eyedrop formulation platform is exciting for future @ARVOinfo scientists of all ages! #cureblindness https://t.co/B85zCSZh0Z
Thursday, February 16th, 2017 at 9:31am
Ionis and Akcea Close on Strategic Collaboration with Novartis on AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx. $IONS https://t.co/z4875I5eey
Ophthalmic Contract Research